Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma

European Journal of Cancer

Volumn 48, Issue 5, 2012, Pages 695-702

  Egberts, Friederike ^a   Kotthoff, Eva Maria ^a   Gerdes, Sascha ^a   Egberts, Jan Hendrik ^a   Weichenthal, Michael ^a   Hauschild, Axel ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

LDH; Metastatic melanoma; Prognosis; S100B; Serum marker; YKL 40

Indexed keywords

CARBOPLATIN; CARBOPLATIN PLUS PACLITAXEL; DACARBAZINE; ELESCLOMOL; ELESCLOMOL PLUS PACLITAXEL; FOTEMUSTINE; LACTATE DEHYDROGENASE; PACLITAXEL; PEGINTERFERON ALPHA2A; PEGYLATED INTERFERON ALPHA2B PLUS SORAFENIB; PROTEIN S100B; SORAFENIB; TUMOR MARKER; UNCLASSIFIED DRUG; YKL 40;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; MALE; MELANOMA; METASTASIS; METASTATIC MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

ADIPOKINES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LECTINS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; NERVE GROWTH FACTORS; PROGNOSIS; S100 PROTEINS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84858700106     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.08.007     Document Type: Article

References (36)

1. C.M. Balch, S.J. Soong, and J.E. Gershenwald Prognostic factors analysis of 17, 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system J Clin Oncol 19 16 2001 3622 3634 (Pubitemid 32786275)
2. M. Deichmann, A. Benner, and M. Bock S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma J Clin Oncol 17 6 1999 1891 1896 (Pubitemid 29269262)
3. C.L. Huang, N. Provost, and A.A. Marghoob Laboratory tests and imaging studies in patients with cutaneous malignant melanoma J Am Acad Dermatol 39 3 1998 451 463 (Pubitemid 28417384)
4. L. Brochez, and J.M. Naeyaert Serological markers for melanoma Br J Dermatol 143 2 2000 256 268 (Pubitemid 30650391)
5. C.M. Balch, A.C. Buzaid, and S.J. Soong Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma J Clin Oncol 19 16 2001 3635 3648 (Pubitemid 32786276)
6. A. Hauschild, G. Engel, and W. Brenner S100B protein detection in serum is a significant prognostic factor in metastatic melanoma Oncology 56 4 1999 338 344 (Pubitemid 29240361)
7. E.D. Martenson, L.O. Hansson, and B. Nilsson Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma J Clin Oncol 19 3 2001 824 831 (Pubitemid 32119098)
8. E.S. Schultz, T.L. Diepgen, and P. Von Den Driesch Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma Br J Dermatol 138 3 1998 426 430 (Pubitemid 28145509)
9. A.A. Tarhini, J. Stuckert, S. Lee, C. Sander, and J.M. Kirkwood Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694 J Clin Oncol 27 1 2009 38 44
10. M.G. Bouwhuis, S. Suciu, and W. Kruit Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: A corollary study to EORTC trial 18952 Eur J Cancer 47 3 2010 361 368
11. A. Hauschild, J. Michaelsen, and W. Brenner Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients Melanoma Res 9 2 1999 155 161 (Pubitemid 29331524)
12. C.S. Jury, E.J. McAllister, and R.M. MacKie Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma Br J Dermatol 143 2 2000 269 274 (Pubitemid 30650392)
13. A.P. Hamberg, C.M. Korse, J.M. Bonfrer, and G.C. de Gast Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma Melanoma Res 13 1 2003 45 49 (Pubitemid 36269813)
14. G. Krahn, P. Kaskel, and S. Sander S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase Anticancer Res 21 2B 2001 1311 1316 (Pubitemid 32494139)
15. C. Schmitz, W. Brenner, E. Henze, E. Christophers, and A. Hauschild Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients Anticancer Res 20 6D 2000 5059 5063 (Pubitemid 32319080)
16. C. Berking, E.M. Schlupen, A. Schrader, J. Atzpodien, and M. Volkenandt Tumor markers in peripheral blood of patients with malignant melanoma: multimarker RT-PCR versus a luminoimmunometric assay for S-100 Arch Dermatol Res 291 9 1999 479 484 (Pubitemid 29484127)
17. F. Egberts, A. Pollex, and J.H. Egberts Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH Onkologie 31 7 2008 380 384 (Pubitemid 351967575)
18. R. Dummer, R. Panizzon, P.H. Bloch, and G. Burg Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma Dermatology 210 1 2005 39 44 (Pubitemid 39656718)
19. C. Garbe, A. Hauschild, and M. Volkenandt Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma Melanoma Res 17 6 2007 393 399 (Pubitemid 350084995)
20. K. Acland, A.V. Evans, and H. Abraha Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma Br J Dermatol 146 2002 832 835 (Pubitemid 34539193)
21. F. Egberts, A. Momkvist, J.H. Egberts, K.C. Kaehler, and A. Hauschild Serum S100B and LDH are not useful in predicting the sentinel node-status in melanoma patients Anticancer Res 30 5 2010 1799 1805
22. B. Volck, P.A. Price, and J.S. Johansen YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils Proc Assoc Am Physicians 110 4 1998 351 360 (Pubitemid 28345905)
23. G.H. Renkema, R.G. Boot, and F.L. Au Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages Eur J Biochem 251 1-2 1998 504 509 (Pubitemid 28080953)
24. A.D. Recklies, C. White, and H. Ling The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways Biochem J 365 Pt 1 2002 119 126 (Pubitemid 34756146)
25. J.S. Johansen, L. Drivsholm, P.A. Price, and I.J. Christensen High serum YKL-40 level in patients with small cell lung cancer is related to early death Lung cancer 46 3 2004 333 340 (Pubitemid 39487308)
26. B.V. Jensen, J.S. Johansen, and P.A. Price High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer Clin Cancer Res 9 12 2003 4423 4434 (Pubitemid 37248400)
27. C. Cintin, J.S. Johansen, and I.J. Christensen Serum YKL-40 and colorectal cancer Br J Cancer 79 9-10 1999 1494 1499 (Pubitemid 29116810)
28. H. Dehn, E.V. Hogdall, and J.S. Johansen Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer Acta Obstet Gynecol Scand 82 3 2003 287 293 (Pubitemid 36459738)
29. H. Schmidt, J.S. Johansen, and P. Sjoegren Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma J Clin Oncol 24 5 2006 798 804 (Pubitemid 46622047)
30. H. Schmidt, J.S. Johansen, and J. Gehl Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma Cancer 106 5 2006 1130 1139
31. G. Ghanem, B. Loir, and R. Morandini On the release and half-life of S100B protein in the peripheral blood of melanoma patients Int J Cancer 94 4 2001 586 590
32. F. Egberts, W.N. Hitschler, M. Weichenthal, and A. Hauschild Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse Melanoma Res 19 1 2009 31 35
33. A. Hauschild, G. Engel, and W. Brenner Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy Br J Dermatol 140 1999 1065 1071 (Pubitemid 29284578)
34. C. Krogh, and Bouwhuis Prognostic value of serum YKL-40 in stage IIB-III melanoma patients receiving adjuvant interferone therapy J Clin Oncol 28 15 2010 A8587
35. L.M. Shackelton, D.M. Mann, and A.J. Millis Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling J Biol Chem 270 22 1995 13076 13083
36. B. Volck, J.S. Johansen, and M. Stoltenberg Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology Osteoarthritis Cartilage 9 3 2001 203 214 (Pubitemid 32390204)